Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
Abstract Introduction Financial relationships between pharmaceutical companies and dementia clinical practice guideline (CPG) authors are possibly biasing the recommendations in Japan. This study aimed to reveal characteristics and distribution of pharmaceutical payments made to Japanese dementia CP...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1016/j.trci.2019.05.003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Introduction Financial relationships between pharmaceutical companies and dementia clinical practice guideline (CPG) authors are possibly biasing the recommendations in Japan. This study aimed to reveal characteristics and distribution of pharmaceutical payments made to Japanese dementia CPG authors and an extent of the transparency in the conflicts of interest disclosure among them. Methods We retrospectively retrieved the publicly available data on payment to all the authors in the dementia CPGs by major pharmaceutical companies in Japan in 2016. Results The total and mean payment values from pharmaceutical companies were $880,061 and $14,427, respectively. Of the 61 authors, 49 (80.3%) physicians received at least one payment. Financial relationships of the individual authors were not disclosed in the CPGs. Discussion Pharmaceutical companies with antidementia drugs had strong financial relationships with the CPG authors. To guarantee fairness in their relationships, it is imperative to establish a framework to disclose the corporate financial conflicts of interest. |
|---|---|
| ISSN: | 2352-8737 |